Abstracts tagged "Activity score"

Abstract Number: 1311 • 2013 ACR/ARHP Annual Meeting
Aiming Simple Disease Activity Score Remission At One Year Leads To Better 3-Year Radiographic and Functional Outcomes Than aiming low Disease activity in Early Rheumatoid Arthritis Patients Treated In Routine Practice. Data From Espoir Cohort
Adeline Ruyssen-Witrand¹, Gregory Guernec², Delphine Nigon³, Gabriel Tobon⁴, Bénédicte Jamard⁵, Anne-Christine Rat⁶, Olivier Vittecoq⁷, Alain G. Cantagrel⁸ and Arnaud L. Constantin¹, ¹Rheumatology, Purpan University Hospital, Toulouse, France, ²UMR 1027, Inserm, Toulouse, France, ³Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴Unit of immunology, Brest, France, ⁵Toulouse University Hospital, Toulouse, France, ⁶Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ⁷Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁸Centre Hospitalier Universitaire de Toulouse, Toulouse, France
Background/Purpose: The ultimate goal of Disease Modifying Anti-Rheumatic Drugs (DMARDs) treatment in early rheumatoid arthritis (RA) is to achieve remission in order to prevent structural…
Abstract Number: 2521 • 2013 ACR/ARHP Annual Meeting
Correlation Of Anti Single and Double Stranded DNA Antibodies and Disease Activity In Systemic Lupus Erythematosus
Cecilia Catoggio, Cecilia Reimundes and Carlos Edgardo Perandones, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina
Background/Purpose: Anti DNA antibodies are considered a hallmark of systemic lupus erythematosus (SLE). Anti double stranded DNA antibody (dsDNA) is part of the SLE classification…
Abstract Number: 2511 • 2013 ACR/ARHP Annual Meeting
Multicenter Validation Of The Lupus Activity Scoring Tool (LAST) As Compared To The Selena Sledai (SS) Modification
Majed M. Khraishi¹, Rana Aslanov², Sanjay Dixit³, Krista Fudge⁴, Vandana Ahluwalia⁵ and Sarah Khraishi⁶, ¹Nexus Clinical Research, St John's, NF, Canada, ²Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, ⁵Past President, Ontario Rheumatology Association, Brampton, ON, Canada, ⁶Nexus Clinical Research, Memorial University of Newfoundland, St.John's, NF, Canada

Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic immune modulated disease with variable clinical manifestations. New advances in the management of SLE mandated closer monitoring…
Abstract Number: 2475 • 2013 ACR/ARHP Annual Meeting
Relationship Between Extra-Articular Manifestations and Disease Activity In Patients Diagnosed With New-Onset Spondyloarthropathy In a Cohort In Spain
César Antonio Egües Dubuc¹, Maria Martin Martinez², Joaquin Belzunegui Otano¹, Miren Uriarte Ecenarro¹, Juan Mulero³, Eugenio de Miguel⁴, Santiago Muñoz⁵, Pedro Zarco⁶, Eduardo Collantes⁷, Sabina Perez Vicente² and Milena Gobbo², ¹Rheumatology, Donostia University Hospital, San Sebastián, Spain, ²Research Unit, Spanish Society of Rheumatology., Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, ⁴Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain, ⁵Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ⁶Rheumatology Service, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, ⁷Rheumatology, Hospital Reina Sofia, Cordoba, Spain
Background/Purpose : The Spondyloarthropathy (SpA) that affect in many aspects of life of the patients, either for their musculoskeletal or extra-articular manifestations (EAM). EAM vary…
Abstract Number: 2395 • 2013 ACR/ARHP Annual Meeting
Plasma Short-Talin Is a New Rheumatoid Arthritis Monitoring Biomarker Independent Of The Inflammatory Markers
Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan
Methods: ). Sixteen (31.4 %) of these 51 patients were untreated, and 18 patients (35.3%) were treated with biologics DMARD at the time of collecting…
Abstract Number: 2289 • 2013 ACR/ARHP Annual Meeting
Correlation Of Anti-Citrullinated Protein and Anti-Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis
Michael Mahler¹, Gabriella Lakos¹, Tyler Webb¹, Alvin Yee¹, Leendert A. Trouw² and Pier-Luigi Meroni³, ¹Research, INOVA Diagnostics, San Diego, CA, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Int Medicine, University of Milan, Milano, Italy
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are important serological markers in the diagnosis of rheumatoid arthritis (RA) and are part of the…
Abstract Number: 2248 • 2013 ACR/ARHP Annual Meeting
Difference Between The Two Versions Of Disease Activity Score Based On C-Reactive Protein and Erythrocyte Sedimentation Rate
Pinar Cetin¹, Dilek Solmaz¹, Hacer Gulluoglu², Ismail Sari¹, Merih Birlik¹, Servet Akar¹, Fatos Onen¹ and Nurullah Akkoc¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Internal Medicine, Dokuz Eylul University School of Medicine, Ýzmir, Turkey

Background/Purpose: In some countries reimbursement criteria require a DAS28 score of >5.1 for initiating anti-TNF therapy in patients with rheumatoid arthritis. DAS28 score can be…
Abstract Number: 1669 • 2013 ACR/ARHP Annual Meeting
The Birmingham Vasculitis Activity Score As a Measure Of Disease Activity In Patients With Giant Cell Arteritis
Tanaz A. Kermani¹, David Cuthbertson², Simon Carette³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Kathleen McKinnon-Maksimowicz⁸, Carol McAlear⁹, Paul A. Monach¹⁰, Philip Seo¹¹, Kenneth J. Warrington¹², Steven R. Ytterberg¹³, Peter A Merkel¹⁴ and Eric L. Matteson¹⁵, ¹Rheumatology, University of California Los Angeles, Los Angeles, CA, ²Department of Biostatistics, University of South Florida, Tampa, FL, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology, Boston University, Boston, MA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹³Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁴Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: To evaluate the performance of the Birmingham Vasculitis Activity Score (BVAS), a validated tool for assessment of vasculitis disease activity, in a cohort…
Abstract Number: 1526 • 2012 ACR/ARHP Annual Meeting
Patient Reported Outcomes in ANCA-Associated Vasculitis. A Prospective Comparison Between Birmingham Vasculitis Activity Score and Routine Assessment of Patient Index Data 3
Osama ElSallabi¹, Joel A. Block¹ and Antoine Sreih², ¹Section of Rheumatology, Rush University Medical Center, Chicago, IL, ²Medicine/Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare group of diseases comprising Granulomatosis with polyangiitis (Wegener’s; GPA), Microscopic Polyangiitis (MPA), and Churg-Strauss Syndrome (CSS). These diseases…
Abstract Number: 319 • 2012 ACR/ARHP Annual Meeting
Gamma Interferon-Induced Protein-10 (IP-10) As a Potential Biomarker for Disease Activity in Pediatric Localized Scleroderma
Katherine Kurzinski¹, Carol A. Feghali-Bostwick², Christina Kelsey¹, Kelsey Magee³ and Kathryn S. Torok⁴, ¹Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune disease affecting the skin and underlying tissue. Cutaneous findings assist in categorizing the patients into active or…
Abstract Number: 1358 • 2012 ACR/ARHP Annual Meeting
Performance of Remission Criteria and Activity Indices in Psoriatic Arthritis
Maria L. Acosta Felquer¹, Leandro Ferreyra Garrott², Erika Catay³, Josefina Marin⁴, Marina Scolnik⁵, Maria Victoria Garcia⁵, Santiago Ruta², Mirtha Sabelli⁶, Zaida Bedran⁶, Javier Rosa³, Luis J. Catoggio⁷ and Enrique R. Soriano⁷, ¹Internal Medicine, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Internal Services, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM. Catoggio, Buenos Aires, Argentina
Background/Purpose: Remission criteria and activity indices used in rheumatoid arthritis (RA) are often applied in psoriatic arthritis (PsA). Although indices have been specifically developed for…
Abstract Number: 277 • 2012 ACR/ARHP Annual Meeting
Dyslipidemia in Juvenile Dermatomyositis: The Role of Disease Activity
Katia T. Kozu¹, Clovis Artur Silva², Eloisa Bonfa³, Adriana M. Sallum⁴, Rosa M.R. Pereira⁵, Vilma S. Viana⁶, Eduardo F. Borba⁷ and Lucia M. A. Campos⁴, ¹Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, University of São Paulo, São Paulo, Brazil, ⁶Rheumatology Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Dyslipidemia has been infrequently investigated in pediatric population with autoimmune rheumatic diseases. However, lipid abnormalities in these diseases may occur due to multiple risk…
Abstract Number: 1297 • 2012 ACR/ARHP Annual Meeting
Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis — Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year
Ronald F. van Vollenhoven¹, Sriram Krishnaswami², Birgitta Benda³, David Gruben⁴, Bethanie Wilkinson⁴, Charles A. Mebus⁴, Samuel H. Zwillich² and John Bradley², ¹Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT, ³Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This post-hoc analysis of the…
Abstract Number: 128 • 2012 ACR/ARHP Annual Meeting
Quantitative Assessment of Synovitis in Patients with Rheumatoid Arthritis Using Fluorescence Optical Imaging
Valentin S. Schäfer¹, Wolfgang Hartung², Patrick Hoffstetter³, Jörn Berger⁴, Martina Müller⁵, Martin Fleck² and Boris P. Ehrenstein², ¹Rheumatology & Clinical Immunology, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, ²Rheumatology & Clinical Immunology, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, ³Radiology, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, ⁴mivenion GmbH, Berlin, Germany, ⁵Clinic for Internal Medicine I, University Clinic Regensburg, Regensburg
Background/Purpose: To prospectively evaluate quantitative assessment of indocyanine green (ICG)-enhanced fluorescence optical imaging (FOI) for differentiation of synovitic from non-synovitic joints in patients suffering from…
Abstract Number: 1232 • 2012 ACR/ARHP Annual Meeting
Association of Actometer Assessed Physical Activity and Fatigue in Patients with Rheumatoid Arthritis: Patients with a Lower Daily Activity Have More Fatigue
Sanne van Dartel¹, Han Repping-Wuts¹, Dewy van Hoogmoed¹, Hans Knoop², Gijs Bleijenberg¹, Piet L.C. van Riel³ and J. Fransen³, ¹Reumatology 470, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Nijmegen Expert Centre of Chronic Fatigue, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Fatigue in rheumatoid arthritis (RA) is related to pain and disability, and several psycho-social factors such as coping strategies. In Chronic Fatigue Syndrome (CFS),…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].